2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Folate Receptor (FR)
  5. FR-α Isoform

FR-α

Folate receptor alpha (FR-α, FOLR1) is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein that binds folate with high affinity and mediates cellular uptake of physiologic folate required for DNA synthesis, repair, and cellular proliferation[1][2]. Mechanistically, FR-α contributes to folate-dependent metabolic processes that support nucleotide biosynthesis and sustained growth of rapidly dividing cells, and elevated FR-α expression has been associated with tumor progression in multiple epithelial malignancies[1][3]. In disease settings, FR-α is highly expressed in ovarian, lung, breast, endometrial, and other epithelial cancers, whereas its expression in normal tissues is comparatively restricted, making it a valuable experimental biomarker and therapeutic target[3][4][5]. Compared with related folate receptor isoforms, FR-α and FR-β share high folate-binding affinity but exhibit distinct tissue distributions; FR-α is predominantly associated with epithelial tissues and epithelial-derived tumors, whereas FR-β is largely restricted to cells of myeloid lineage and macrophage populations[4][6]. This isoform-specific expression pattern is particularly important for experimental design because it enables selective interrogation of tumor-associated folate biology while minimizing overlap with immune-cell-associated folate receptor signaling[4][6]. For research and translational applications, FR-α has been extensively investigated as a target for antibody-based therapeutics, folate-conjugated agents, imaging probes, and antibody-drug conjugates that exploit receptor-mediated internalization in FR-α-positive tumors[5][7][8]. Therefore, FR-α serves as both a functional mediator of folate utilization and a clinically relevant molecular target for cancer biology, biomarker development, and targeted therapeutic research[3][5][7].

FR-α Related Products (6):

Cat. No. Product Name Effect Purity
  • HY-P992124
    Onvontatug
    		Inhibitor
    Onvontatug (BAT8006 Antibody) is a humanized monoclonal antibody targeting folate receptor α (FRα). Onvontatug can be used to construct antibody-drug conjugates (ADCs), such as BAT8006. It is applicable to research related to platinum-resistant ovarian cancer.
  • HY-185743
    ZW-191
    ZW-191 is an antibody-drug conjugate (ADC) targeting folate receptor α (FRα). ZW-191 consists of ZW-191 Antibody (HY-P992515) as the antibody component and MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) as the linker-payload component. ZW-191 possesses excellent tumor sphere penetration, cellular internalization and payload delivery capabilities, and can release a topoisomerase 1 inhibitor inside tumor cells to inhibit tumor cell activity. ZW-191 exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 exhibits prominent activity in xenograft models of cell lines with different FRα expression levels. ZW-191 can be used in studies related to ovarian cancer, non-small cell lung cancer, endometrial cancer and triple-negative breast cancer.
  • HY-P992515
    ZW-191 Antibody
    ZW-191 Antibody is a humanized IgG1 antibody targeting folate receptor α (FRα). ZW-191 Antibody is conjugated with MC-GGFG-AM-(10Me-11F-Camptothecin) (HY-153360) to generate the antibody-drug conjugate (ADC) ZW-191 (HY-185743). ZW-191 Antibody-based ADC exerts a potent bystander effect on both antigen-positive and antigen-negative cells. ZW-191 Antibody is applicable to research related to ovarian cancer, non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • HY-180557
    4A-BFA-11
    4A-BFA-11 is a folate-targeted PEG-MMAE conjugate that exhibits specific binding affinity for the folate receptor α (FR-α) (KD = 106.7 nM). 4A-BFA-11 achieves tumor enrichment by combining PEG-mediated long circulation (EPR effect) and folate receptor targeting. 4A-BFA-11 undergoes enzymatic cleavage at the tumor site to release the active payload, enabling precise action. 4A-BFA-11 sefficiently carries, targets, and controls the release of MMAE in tumor tissues in a HeLa mouse model. 4A-BFA-11 can be used for cervical cancer, ovarian cancer, and lung cancer research.
  • HY-185773A
    Farletuzumab-LNK4-S (DAR4)
    		Inhibitor
    Farletuzumab-LNK4-S (DAR4) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 4. Farletuzumab-LNK4-S (DAR4) is prepared by conjugating the anti-FRα antibody Farletuzumab (HY-P99153) with LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR4) can be used in cancer-related research.
  • HY-185773
    Farletuzumab-LNK4-S (DAR8)
    Farletuzumab-LNK4-S (DAR8) is an antibody-drug conjugate (ADC) with a drug-to-antibody ratio of 8. Farletuzumab-LNK4-S (DAR8) is conjugated from the anti-FRα antibody Farletuzumab (HY-P99153) and LNK4-S (HY-170400). Farletuzumab-LNK4-S (DAR8) can be used in cancer-related research.